- Home
- SKIN vs SAVA Comparison
SKIN vs SAVA Comparison
Compare SKIN & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKIN
- SAVA
- Stock Information
- Founded
- SKIN 1997
- SAVA 1998
- Country
- SKIN United States
- SAVA United States
- Employees
- SKIN N/A
- SAVA N/A
- Industry
- SKIN Package Goods/Cosmetics
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- SKIN Consumer Discretionary
- SAVA Health Care
- Exchange
- SKIN Nasdaq
- SAVA Nasdaq
- Market Cap
- SKIN 176.3M
- SAVA 157.5M
- IPO Year
- SKIN N/A
- SAVA N/A
- Fundamental
- Price
- SKIN $1.39
- SAVA $2.94
- Analyst Decision
- SKIN Buy
- SAVA Buy
- Analyst Count
- SKIN 3
- SAVA 2
- Target Price
- SKIN $2.42
- SAVA $5.00
- AVG Volume (30 Days)
- SKIN 1.3M
- SAVA 1.9M
- Earning Date
- SKIN 11-06-2025
- SAVA 11-07-2025
- Dividend Yield
- SKIN N/A
- SAVA N/A
- EPS Growth
- SKIN N/A
- SAVA N/A
- EPS
- SKIN N/A
- SAVA N/A
- Revenue
- SKIN $301,917,000.00
- SAVA N/A
- Revenue This Year
- SKIN N/A
- SAVA N/A
- Revenue Next Year
- SKIN $5.61
- SAVA N/A
- P/E Ratio
- SKIN N/A
- SAVA N/A
- Revenue Growth
- SKIN N/A
- SAVA N/A
- 52 Week Low
- SKIN $0.78
- SAVA $1.15
- 52 Week High
- SKIN $2.69
- SAVA $33.98
- Technical
- Relative Strength Index (RSI)
- SKIN 44.86
- SAVA 38.68
- Support Level
- SKIN $1.25
- SAVA $3.62
- Resistance Level
- SKIN $1.49
- SAVA $3.06
- Average True Range (ATR)
- SKIN 0.13
- SAVA 0.25
- MACD
- SKIN 0.02
- SAVA -0.15
- Stochastic Oscillator
- SKIN 35.71
- SAVA 9.51
About SKIN The Beauty Health Company
The Beauty Health Co is a category-creating beauty health company that along with its subsidiaries designs, develops, manufactures, markets and sells esthetic technologies and products. The company's brand portfolio includes Hydrafacial, SkinStylus, and Keravive, offering Syndeo device, SkinStylus SteriLock Microsystem, Keravive Peptide Solution and other products.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.